ZDHHC16

Summary

ZDHHC16 (zDHHC palmitoyltransferase 16, HGNC:20714) is a protein-coding gene on chromosome 10q24.1, encoding Palmitoyltransferase ZDHHC16 (Q969W1). Palmitoyl acyltransferase that mediates palmitoylation of proteins such as PLN and ZDHHC6.

Enables palmitoyltransferase activity. Involved in protein palmitoylation. Predicted to be located in endoplasmic reticulum membrane. Predicted to be active in Golgi apparatus.

Source: NCBI Gene 84287 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neurodevelopmental disorder (Moderate, GenCC)
• GWAS associations: 2
• Clinical variants (ClinVar): 62 total — 2 pathogenic
• MANE Select transcript: NM_198046

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20714
Approved symbol	ZDHHC16
Name	zDHHC palmitoyltransferase 16
Location	10q24.1
Locus type	gene with protein product
Status	Approved
Aliases	APH2
Ensembl gene	ENSG00000171307
Ensembl biotype	protein_coding
OMIM	616750
Entrez	84287

Gene structure

Transcript identifiers

Ensembl transcripts: 51 — 44 protein_coding, 7 protein_coding_CDS_not_defined

ENST00000345745, ENST00000352634, ENST00000353979, ENST00000370842, ENST00000370846, ENST00000370854, ENST00000393760, ENST00000414567, ENST00000417044, ENST00000420089, ENST00000433086, ENST00000459777, ENST00000462924, ENST00000466895, ENST00000487315, ENST00000492610, ENST00000492733, ENST00000495735, ENST00000862039, ENST00000862040, ENST00000862041, ENST00000862042, ENST00000862043, ENST00000862044, ENST00000862045, ENST00000862046, ENST00000862047, ENST00000862048, ENST00000862049, ENST00000862050, ENST00000862051, ENST00000862052, ENST00000862053, ENST00000862054, ENST00000862055, ENST00000862056, ENST00000862057, ENST00000862058, ENST00000916030, ENST00000916031, ENST00000951305, ENST00000951306, ENST00000951307, ENST00000951308, ENST00000951309, ENST00000951310, ENST00000951311, ENST00000951312, ENST00000951313, ENST00000951314, ENST00000951315

RefSeq mRNA: 7 — MANE Select: NM_198046 NM_001287803, NM_001287804, NM_032327, NM_198043, NM_198044, NM_198045, NM_198046

CCDS: CCDS73176, CCDS7460, CCDS7461, CCDS7462, CCDS7463

Canonical transcript exons

ENST00000393760 — 12 exons

Exon	Start	End
ENSE00001453754	97446175	97446353
ENSE00001516435	97450357	97450536
ENSE00003476610	97453530	97453663
ENSE00003503376	97454714	97454799
ENSE00003526332	97452090	97452284
ENSE00003533038	97452415	97452503
ENSE00003538136	97452895	97452923
ENSE00003553327	97453799	97453846
ENSE00003554372	97455974	97456044
ENSE00003583695	97451671	97451918
ENSE00003657439	97455660	97455783
ENSE00003893408	97456777	97457370

Expression profiles

Bgee: expression breadth ubiquitous, 255 present calls, max score 97.45.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 21.0477 / max 148.7481, expressed in 1805 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
106434	18.0605	1805
106435	2.9872	1487

Top tissues by expression

256 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pancreatic ductal cell	CL:0002079	97.45	gold quality
parotid gland	UBERON:0001831	96.25	gold quality
stromal cell of endometrium	CL:0002255	92.94	gold quality
metanephros cortex	UBERON:0010533	92.19	gold quality
mucosa of transverse colon	UBERON:0004991	92.17	gold quality
adenohypophysis	UBERON:0002196	92.00	gold quality
ileal mucosa	UBERON:0000331	91.67	gold quality
body of pancreas	UBERON:0001150	91.59	gold quality
saliva-secreting gland	UBERON:0001044	91.57	gold quality
tibialis anterior	UBERON:0001385	91.43	gold quality
middle temporal gyrus	UBERON:0002771	91.43	gold quality
epithelial cell of pancreas	CL:0000083	91.41	silver quality
upper lobe of left lung	UBERON:0008952	91.36	gold quality
minor salivary gland	UBERON:0001830	91.21	gold quality
upper lobe of lung	UBERON:0008948	91.21	gold quality
body of stomach	UBERON:0001161	91.20	gold quality
right hemisphere of cerebellum	UBERON:0014890	90.82	gold quality
oocyte	CL:0000023	90.75	gold quality
rectum	UBERON:0001052	90.75	gold quality
pituitary gland	UBERON:0000007	90.73	gold quality
lower esophagus mucosa	UBERON:0035834	90.71	gold quality
pancreas	UBERON:0001264	90.70	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	90.67	gold quality
islet of Langerhans	UBERON:0000006	90.67	gold quality
apex of heart	UBERON:0002098	90.62	gold quality
right lobe of liver	UBERON:0001114	90.56	gold quality
placenta	UBERON:0001987	90.55	gold quality
stomach	UBERON:0000945	90.41	gold quality
right lobe of thyroid gland	UBERON:0001119	90.29	gold quality
cerebellar hemisphere	UBERON:0002245	90.14	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	9.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

34 targeting ZDHHC16, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-22-3P	99.93	68.13	917
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-6838-5P	99.89	71.94	2690
HSA-MIR-424-5P	99.89	71.90	2641
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-3934-5P	99.67	64.04	846
HSA-MIR-18A-3P	99.56	65.68	1092
HSA-MIR-6081	99.48	66.07	1446
HSA-MIR-1324	99.46	66.57	1302
HSA-MIR-4251	99.40	69.19	3363
HSA-MIR-3182	99.40	68.15	2454
HSA-MIR-4786-3P	99.36	68.35	1390
HSA-MIR-4999-5P	99.35	69.15	926
HSA-MIR-4254	99.11	65.15	1315
HSA-MIR-5197-3P	98.71	67.05	1905
HSA-MIR-6830-3P	98.62	68.07	1760
HSA-MIR-4718	98.55	68.61	814
HSA-MIR-6792-5P	98.39	68.16	1330
HSA-MIR-4443	98.02	66.25	1928
HSA-MIR-4468	98.01	66.85	1187
HSA-MIR-6787-3P	97.75	66.17	1233

Literature-anchored findings (GeneRIF, showing 4)

• APH2 contains a zf-DHHC domain (148-210aa), which is involved in protein-protein or protein-DNA interaction. (PMID:17123647)
• human ZDHHC6, which modifies key proteins of the endoplasmic reticulum, is controlled by an upstream palmitoyltransferase, ZDHHC16, revealing the first palmitoylation cascade. (PMID:28826475)
• SETD2 Palmitoylation Mediated by ZDHHC16 in Epidermal Growth Factor Receptor-Mutated Glioblastoma Promotes Ionizing Radiation-Induced DNA Damage. (PMID:35192890)
• METTL3-mediated m6A modification enhances ZDHHC16 expression in nonsmall- cell lung cancer patients, attenuating ferroptosis by suppressing CREB ubiquitination. (PMID:38430044)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	zdhhc16a	ENSDARG00000007808
danio_rerio	zdhhc16b	ENSDARG00000015989
mus_musculus	Zdhhc16	ENSMUSG00000025157
rattus_norvegicus	Zdhhc16	ENSRNOG00000046530
drosophila_melanogaster	CG5880	FBGN0039489

Protein

Protein identifiers

Palmitoyltransferase ZDHHC16 — Q969W1 (reviewed: Q969W1)

Alternative names: Abl-philin 2, Zinc finger DHHC domain-containing protein 16

All UniProt accessions (6): B1AMT9, B1AMU0, B1AMU5, Q969W1, H0Y536, H0Y6E9

UniProt curated annotations — full annotation on UniProt →

Function. Palmitoyl acyltransferase that mediates palmitoylation of proteins such as PLN and ZDHHC6. Required during embryonic heart development and cardiac function, possibly by mediating palmitoylation of PLN, thereby affecting PLN phosphorylation and homooligomerization. Also required for eye development. Palmitoylates ZDHHC6, affecting the quaternary assembly of ZDHHC6, its localization, stability and function. May play a role in DNA damage response. May be involved in apoptosis regulation. Involved in the proliferation of neural stem cells by regulating the FGF/ERK pathway.

Subunit / interactions. Interacts with ABL1. Interacts with COPS5/JAB1.

Subcellular location. Endoplasmic reticulum membrane.

Tissue specificity. Widely expressed.

Domain organisation. The DHHC domain is required for palmitoyltransferase activity.

Similarity. Belongs to the DHHC palmitoyltransferase family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q969W1-1	1	yes
Q969W1-2	2
Q969W1-3	3
Q969W1-4	4

RefSeq proteins (7): NP_001274732, NP_001274733, NP_115703, NP_932160, NP_932161, NP_932162, NP_932163* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001594	Palmitoyltrfase_DHHC	Domain
IPR039859	PFA4/ZDH16/20/ERF2-like	Family

Pfam: PF01529

Enzyme classification (BRENDA):

• EC 2.3.1.225 — protein S-acyltransferase (BRENDA: 9 organisms, 108 substrates, 15 inhibitors, 6 Km, 0 kcat entries)

Substrate kinetics (BRENDA)

2 substrates with measured Km, best-characterized 2. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
PALMITOYL-COA	0.0052–0.0059	2
[N-MYRISTOYLATED GLY-CYS-GLY TRIPEPTIDE]-L-CYSTE	0.0008–0.0013	2

Catalyzed reactions (Rhea), 1 shown:

• L-cysteinyl-[protein] + hexadecanoyl-CoA = S-hexadecanoyl-L-cysteinyl-[protein] + CoA (RHEA:36683)

UniProt features (15 total): topological domain 5, transmembrane region 4, splice variant 3, chain 1, domain 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q969W1-F1	87.96	0.67

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 185 (s-palmitoyl cysteine intermediate)

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 89 (showing top): STARK_PREFRONTAL_CORTEX_22Q11_DELETION_DN, GOBP_FOREBRAIN_DEVELOPMENT, GOBP_DNA_DAMAGE_RESPONSE, GARY_CD5_TARGETS_DN, GOBP_HEAD_DEVELOPMENT, MARTINEZ_RESPONSE_TO_TRABECTEDIN_DN, GOBP_SENSORY_ORGAN_DEVELOPMENT, TGCCTTA_MIR124A, GOBP_TELENCEPHALON_DEVELOPMENT, GOBP_CIRCULATORY_SYSTEM_DEVELOPMENT, GOCC_NUCLEAR_OUTER_MEMBRANE_ENDOPLASMIC_RETICULUM_MEMBRANE_NETWORK, GOCC_ORGANELLE_SUBCOMPARTMENT, GOMF_S_ACYLTRANSFERASE_ACTIVITY, GOMF_PALMITOYLTRANSFERASE_ACTIVITY, GOMF_ACYLTRANSFERASE_ACTIVITY

GO Biological Process (6): eye development (GO:0001654), apoptotic process (GO:0006915), DNA damage response (GO:0006974), heart development (GO:0007507), telencephalon development (GO:0021537), fibroblast growth factor receptor signaling pathway involved in forebrain neuron fate commitment (GO:0021899)

GO Molecular Function (5): palmitoyltransferase activity (GO:0016409), protein-cysteine S-palmitoyltransferase activity (GO:0019706), protein binding (GO:0005515), transferase activity (GO:0016740), acyltransferase activity (GO:0016746)

GO Cellular Component (4): endoplasmic reticulum membrane (GO:0005789), Golgi apparatus (GO:0005794), endoplasmic reticulum (GO:0005783), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cytoplasm	2
endomembrane system	2
intracellular membrane-bounded organelle	2
sensory organ development	1
visual system development	1
programmed cell death	1
apoptotic signaling pathway	1
execution phase of apoptosis	1
cellular response to stress	1
animal organ development	1
circulatory system development	1
forebrain development	1
anatomical structure development	1
fibroblast growth factor receptor signaling pathway	1
forebrain neuron fate commitment	1
commitment of multipotent stem cells to neuronal lineage in forebrain	1
acyltransferase activity, transferring groups other than amino-acyl groups	1
palmitoyltransferase activity	1
protein-cysteine S-acyltransferase activity	1
binding	1
catalytic activity	1
transferase activity	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
cellular anatomical structure	1

Protein interactions and networks

STRING

640 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZDHHC16	ABL1	P00519	750
ZDHHC16	ZDHHC5	Q9C0B5	545
ZDHHC16	ZDHHC3	Q9NYG2	542
ZDHHC16	LYPLA2	O95372	516
ZDHHC16	ABHD17A	Q96GS6	505
ZDHHC16	GOLGA7	Q7Z5G4	490
ZDHHC16	LYPLA1	O75608	474
ZDHHC16	ZDHHC21	Q8IVQ6	474
ZDHHC16	PPT2	Q9UMR5	430
ZDHHC16	GOLGA7B	Q2TAP0	427
ZDHHC16	ZDHHC13	Q8IUH4	427
ZDHHC16	PGP	A6NDG6	423
ZDHHC16	ZDHHC8	Q9ULC8	422
ZDHHC16	PPT1	P50897	412
ZDHHC16	DCUN1D2	Q6PH85	411

IntAct

11 interactions, top by confidence:

A	B	Type	Score
TMED8	ZDHHC16	psi-mi:“MI:0915”(physical association)	0.560
YIF1A	ZDHHC16	psi-mi:“MI:0915”(physical association)	0.560
ZDHHC16	CRYAA	psi-mi:“MI:0915”(physical association)	0.400
ZDHHC16	MTNR1A	psi-mi:“MI:0915”(physical association)	0.370
CCL1	ZDHHC16	psi-mi:“MI:0915”(physical association)	0.370
ZDHHC16	PCK1	psi-mi:“MI:0914”(association)	0.350
TMED8	ZDHHC16	psi-mi:“MI:0915”(physical association)	0.000
YIF1A	ZDHHC16	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (11): ZDHHC16 (Two-hybrid), ZDHHC16 (Two-hybrid), YIF1A (Two-hybrid), ZDHHC16 (Two-hybrid), ZDHHC16 (Affinity Capture-Western), ZDHHC16 (Affinity Capture-RNA), CRYAA (Affinity Capture-MS), PCK1 (Affinity Capture-MS), PDXP (Affinity Capture-MS), ZDHHC16 (Protein-RNA), ZDHHC16 (Affinity Capture-RNA)

ESM2 similar proteins: A0A0R4IF99, B8A4F0, E7F587, E7F6D7, F1Q7H8, F1QHM7, F1QX91, F1QXD3, F1RE57, O14345, O74384, P0C7U3, P42836, Q06551, Q0VC89, Q10L01, Q14AK4, Q2HJ95, Q2TGJ4, Q3EBC2, Q4R7E2, Q4WN54, Q58CU4, Q5BC23, Q5BLG4, Q5FWL7, Q5REH2, Q5W0Z9, Q5Y5T1, Q5Y5T3, Q6BLY8, Q6CG20, Q6CUB5, Q6DHI1, Q6FSS4, Q750R7, Q75AW7, Q76IC6, Q7XA86, Q8BGJ0

Diamond homologs: A0A0R4IF99, A5WVX9, B8A4F0, E7F587, E9PTT0, F1Q7H8, F1QXD3, P0CS66, P0CS67, P42836, P59267, Q2TGJ4, Q2TGK3, Q4R7E2, Q552M6, Q58CU4, Q58DT3, Q59QL0, Q5ADN9, Q5W0Z9, Q6BHT4, Q6C4W5, Q6DHI1, Q6FW70, Q6FXC6, Q80TN5, Q8BGJ0, Q8IUH5, Q8R173, Q8VYP5, Q91WU6, Q923G5, Q969W1, Q96MV8, Q9ESG8, Q9FLM3, Q9JKR5, Q9M1K5, Q9M306, Q9NXF8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

62 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	53
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
3024558	NM_198046.3(ZDHHC16):c.556+2T>C	Pathogenic
3024564	NM_198046.3(ZDHHC16):c.1118_1119del (p.Ser373fs)	Pathogenic

SpliceAI

1867 predictions. Top by Δscore:

Variant	Effect	Δscore
10:97451914:GAGTG:G	donor_gain	1.0000
10:97451916:GTG:G	donor_gain	1.0000
10:97451917:TGG:T	donor_loss	1.0000
10:97451919:G:GG	donor_gain	1.0000
10:97451920:T:A	donor_loss	1.0000
10:97453583:T:A	acceptor_gain	1.0000
10:97453592:A:AG	acceptor_gain	1.0000
10:97453592:AT:A	acceptor_gain	1.0000
10:97453593:T:G	acceptor_gain	1.0000
10:97453797:A:AG	acceptor_gain	1.0000
10:97453798:G:GG	acceptor_gain	1.0000
10:97454712:A:AG	acceptor_gain	1.0000
10:97454713:G:GG	acceptor_gain	1.0000
10:97454713:GACTT:G	acceptor_gain	1.0000
10:97455658:A:AG	acceptor_gain	1.0000
10:97455659:G:GG	acceptor_gain	1.0000
10:97455659:GTTCT:G	acceptor_gain	1.0000
10:97455712:A:AG	acceptor_gain	1.0000
10:97455713:G:GG	acceptor_gain	1.0000
10:97455779:GCAGA:G	donor_gain	1.0000
10:97455782:GA:G	donor_gain	1.0000
10:97455784:G:GG	donor_gain	1.0000
10:97446351:CAGGT:C	donor_loss	0.9900
10:97446352:AGG:A	donor_loss	0.9900
10:97446353:GGTA:G	donor_loss	0.9900
10:97446354:GTAA:G	donor_loss	0.9900
10:97451917:TG:T	donor_gain	0.9900
10:97451918:GG:G	donor_gain	0.9900
10:97452281:CCAG:C	donor_loss	0.9900
10:97452282:CAG:C	donor_loss	0.9900

AlphaMissense

2447 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
10:97452445:T:A	C157S	1.000
10:97452445:T:C	C157R	1.000
10:97452446:G:A	C157Y	1.000
10:97452446:G:C	C157S	1.000
10:97452468:G:C	K164N	1.000
10:97452468:G:T	K164N	1.000
10:97452481:C:G	H169D	1.000
10:97452486:C:A	H170Q	1.000
10:97452486:C:G	H170Q	1.000
10:97452487:T:A	C171S	1.000
10:97452487:T:C	C171R	1.000
10:97452488:G:A	C171Y	1.000
10:97452488:G:C	C171S	1.000
10:97452488:G:T	C171F	1.000
10:97452489:C:G	C171W	1.000
10:97452496:T:C	C174R	1.000
10:97452497:G:A	C174Y	1.000
10:97452498:C:G	C174W	1.000
10:97452910:G:A	M181I	1.000
10:97452910:G:C	M181I	1.000
10:97452910:G:T	M181I	1.000
10:97452911:G:C	D182H	1.000
10:97452912:A:C	D182A	1.000
10:97452912:A:T	D182V	1.000
10:97452914:C:A	H183N	1.000
10:97452914:C:G	H183D	1.000
10:97452915:A:T	H183L	1.000
10:97452916:C:A	H183Q	1.000
10:97452916:C:G	H183Q	1.000
10:97452917:C:A	H184N	1.000

dbSNP variants (sampled 300 via entrez): RS1000058773 (10:97446901 T>A,C), RS1000160925 (10:97450527 G>T), RS1000302752 (10:97455546 G>A,T), RS1000821623 (10:97450157 C>T), RS1001081710 (10:97457417 G>C), RS1001484941 (10:97447304 G>A), RS1001744425 (10:97454184 G>A,C,T), RS1001765543 (10:97455154 A>T), RS1002273091 (10:97448229 A>G), RS1002353746 (10:97455956 T>C), RS1002859793 (10:97446997 C>T), RS1003168469 (10:97446090 C>A,T), RS1003334108 (10:97447216 A>G), RS1003716317 (10:97451806 TCTGC>T), RS1004260260 (10:97449370 A>G)

Disease associations

OMIM: gene MIM:616750 | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
neurodevelopmental disorder	Moderate	Autosomal recessive

Mondo (2): intellectual disability (MONDO:0001071), neurodevelopmental disorder (MONDO:0700092)

Orphanet (1): NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST008178_10	Early spontaneous preterm birth	3.000000e-06
GCST008180_6	Spontaneous preterm birth with premature rupture of membranes	2.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0006917	spontaneous preterm birth

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	increases expression, increases methylation, affects expression	3
Cisplatin	affects expression, increases expression	2
aristolochic acid I	decreases expression	1
triphenyl phosphate	affects expression	1
beta-lapachone	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	decreases expression	1
cobaltous chloride	decreases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
azoxystrobin	decreases expression	1
deguelin	decreases expression	1
ICG 001	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Decitabine	affects expression	1
Acetaminophen	increases expression	1
Air Pollutants, Occupational	decreases expression	1
Atrazine	decreases expression	1
Benzo(a)pyrene	decreases methylation	1
Doxorubicin	decreases expression	1
Nickel	decreases expression	1
Plant Extracts	increases expression, affects cotreatment	1
Rotenone	decreases expression	1
Smoke	decreases expression	1
Thiram	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Cyclosporine	decreases expression	1
Copper Sulfate	decreases expression	1
Acrylamide	decreases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TY73	HAP1 ZDHHC16 (-) 1	Cancer cell line	Male
CVCL_TY74	HAP1 ZDHHC16 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

390 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT05657860	PHASE4	COMPLETED	Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05744479	PHASE4	RECRUITING	Metformin for Antipsychotic-induced Weight Gain in Adults With Intellectual Disability
NCT06107829	PHASE4	WITHDRAWN	Valbenazine Treatment of Tardive Dyskinesia in Adults With Intellectual/Developmental Disabilities
NCT06997198	PHASE4	NOT_YET_RECRUITING	Deutetrabenazine Treatment for Tardive Dyskinesia in Intellectual/Developmental Disabilities
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02270736	PHASE3	COMPLETED	Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT02304302	PHASE2	COMPLETED	Down Syndrome Memantine Follow-up Study
NCT03862950	PHASE2	COMPLETED	A Trial of Metformin in Individuals With Fragile X Syndrome (Met)
NCT04529226	PHASE2	UNKNOWN	Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis
NCT04821856	PHASE2	COMPLETED	Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT05273320	PHASE1	COMPLETED	Clinical Trial of Nabilone for Aggression in Adults With Intellectual and Developmental Disabilities
NCT05301361	PHASE1	ENROLLING_BY_INVITATION	Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities
NCT06016764	PHASE1	COMPLETED	Use of MRI and cTBS for Catatonia in Autism
NCT06586827	PHASE1	COMPLETED	Impact of Competency-Based Training and Technical Assistance Employment Outcomes of Individuals With ID/DD
NCT07531940	PHASE1	NOT_YET_RECRUITING	Escalating Doses of Memantine in Down Syndrome (MEDS-123)
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays